Abciximab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Dipyridamole
Antiplatelet / coronary vasodilator (PDE inhibitor) · Antithrombotic agent
START
MR 200 mg + ASA 25 mg PO twice daily
TYPICAL MAX
400 mg/day (oral)
STOP IF
Angina worsens, syncope, or severe headache intolerance
WATCH
BP, anginal symptoms; reverse stress test with aminophylline
CDSCO approvedSchedule HATC B01AC07
KDIGO 2024 + manufacturer label
- ONSET
- 30min · oral onset
- PEAK
- 1.3h · Tmax
- t½
- 11h · t½
- DURATION
- 8h · BID/QID
EXCRETION
Biliary/faecal enterohepatic; minimal renal
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Limited human data; use only if clearly needed.
FDA category + note
Top interactionssee all 12 →
- AbciximabSevereDatabaseDDInter
- AcalabrutinibSevereDatabaseDDInter
- AdenosineSevereDatabaseKimi deep-research + Cla
- ApixabanSevereDatabaseDDInter
Available in India
6 branded formulations. Look up specific brands in the Drugs workspace.
Mechanism
Inhibits platelet phosphodiesterase and adenosine reuptake, raising cAMP and adenosine — reducing platelet aggregation and causing vasodilation; combined with aspirin for secondary stroke prevention.
Indications
Secondary prevention of ischaemic stroke/TIA (with aspirin)Thromboprophylaxis with prosthetic heart valves (with warfarin)Pharmacological stress agent for myocardial perfusion imaging
Dosing
- Adult
- Antiplatelet: 75–100 mg PO four times daily; modified-release dipyridamole 200 mg + aspirin 25 mg twice daily (Aggrenox). Stress imaging: 0.142 mg/kg/min IV over 4 min.
- Pediatric
- Kawasaki/valve (specialist): 2–5 mg/kg/day divided.
- Renal adjustment
- No specific adjustment.
- Hepatic adjustment
- Caution in significant hepatic impairment (hepatic clearance).
- Geriatric
- No specific adjustment; monitor BP.
- Max dose
- 400 mg/day (oral antiplatelet)
Pharmacokinetics
Onset
~20–30 min (oral); rapid (IV stress)
Peak effect
~75 min (Tmax)
Duration
~8 h
Half-life
Terminal ~10–12 h
Bioavailability
~37–66% (variable, pH-dependent)
Protein binding
~91–99%
Metabolism
Hepatic glucuronidation
Excretion
Biliary/faecal (enterohepatic); minimal renal
Contraindications
- Hypersensitivity
- Caution in unstable angina/recent MI
- Severe coronary artery disease (stress testing — coronary steal)
Side effects
Common
HeadacheDizzinessGI upsetFlushingHypotension
Serious
- Angina aggravation / coronary steal
- Bronchospasm (IV stress test)
- Severe hypotension
- Thrombocytopenia (rare)
Pregnancy & lactation
Pregnancy
Limited human data; use only if clearly needed.
Lactation
Excreted in milk in small amounts; caution.
Drug interactions
Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Adenosine
Severe
Database
Blocked adenosine reuptake potentiates effect
Reduce adenosine dose; avoid within 24 h
Source: Kimi deep-research + Cla
Apixaban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Ardeparin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Argatroban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Avapritinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Betrixaban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cabozantinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cangrelor
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Caplacizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Dalteparin
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Ask House about Dipyridamole
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Harrison 22e, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20